Early Alzheimer’s diagnosis compound


Alzheimer’s disease is the most common form of dementia and, as there is no cure, early diagnosis is crucial for treatment to be effective. To this end, UK and US scientists have developed a labelled tracer compound that binds to plaques closely associated with Alzheimer’s disease (AD) so that the plaques can be picked up by a medical imaging technique.

The tracer compound is a [18F]-labelled barbiturate and is used with the imaging technique positron emission tomography (PET). Although other radiolabelled compounds have been used as PET tracers, using [18F]-labelled barbiturates for molecular imaging in AD has distinct advantages, such as good blood-brain barrier crossing ability, metabolic stability and easy accessibility.

Tree that looks like a face with some leaves blowing away to represent memory loss in Alzheimer's disease

As Alzheimer’s disease advances, symptoms can include confusion, irritability and aggression, and long-term memory loss © Shutterstock

Matteo Zanda at the University of Aberdeen and colleagues, in conjunction with Pfizer in the US, developed several fluorinated barbiturate analogues. The key to developing an effective molecular imaging radiotracer is the ability to distinguish between a healthy individual and someone suffering from a neurological disease, such as AD, they say. Barbiturates have a strong capacity for forming structures with biopolymers and are effective metal ion chelators. As such, the team thought that they would bind to AD-related plaques, which consist of the biopolymer β-amyloid and metal cations, such as Zn(II) and Cu(II).

The team tested the fluorinated barbiturates in healthy mice and mice affected with AD. The results show that the compounds bind to β-amyloid and Zn, and PET imaging showed particularly intense fluorescence in the plaques of AD-affected mice, which was not present in the healthy group. ‘AD is a major unmet medical need and it is clear that a conceptually new class of diagnostic tools for AD could be a major breakthrough,’ says Zanda.

‘There is a clear need to develop a long lived radiotracer,’ says Sibaprasad Bhattacharyya, an expert in radiolabelled PET tracers at the Frederick National Laboratory for Cancer Research, US. ‘The development of a [18F]-labelled barbiturate as a PET tracer for AD is a very clever and thoughtful approach.’

Zanda’s team is continuing to develop more effective PET tracers for AD diagnosis and is looking to further investigate the exact mechanism by which these tracers work.


Related Content

Zinc ruled out as biomarker for Alzheimer’s disease

31 March 2014 Research

news image

Study says decreasing serum zinc levels are a sign of ageing

Renewed focus on dementia checked by drug challenges

3 July 2014 News and Analysis

news image

'Ticking time bomb' of global neurodegenerative disease burden will be difficult to defuse

Most Read

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Takeover battle pushes Allergan to cut R&D jobs

28 July 2014 Business

news image

Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth

Most Commented

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point